Fig. 7. Schematic summary of Salmonella effector SopB reorganizes cytoskeletal vimentin for efficient infection.

Bacterial SopB targets vimentin by its N terminal Cdc42-binding domain to maintain concrete replication vacuoles via activating Cdc42-MEK1/2 signaling axis. Trametinib, identified in the high-content screen, is a clinically approved drug inhibiting MEK1/2, which suppresses Salmonella infection both in vitro and in vivo.